Phase IIb trial of an oral formulation of testosterone undecanoate in adult males with primary or secondary hypogonadism.
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2015
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism
- Focus Therapeutic Use
- Sponsors SOV Therapeutics
- 08 Mar 2015 Results presented at The 97th Annual Meeting of the Endocrine Society.
- 24 Dec 2014 New trial record
- 16 Dec 2014 Primary endpoint has been met (testosterone replacement), according to a SOV Therapeutics media release.